Skip to main content
Erschienen in:

01.04.2019 | Perspective

The Stanley Neuropathology Consortium Integrative Database (SNCID) for Psychiatric Disorders

verfasst von: Sanghyeon Kim, Maree J. Webster

Erschienen in: Neuroscience Bulletin | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Auszug

The Stanley Medical Research Institute (SMRI) is a non-profit organization with a primary mission to fund research on the cause and treatment of severe mental illnesses. The SMRI also supports a brain bank as part of the mission to facilitate research into mental illness. The SMRI brain bank distributes postmortem samples from individuals with serious mental illness, free of charge, to scientists around the world. The SMRI brain bank is recognized for the unique way it is set up, organized, and administered. Cohorts of demographically-matched groups of patients with schizophrenia, bipolar disorder (BP), or major depression (DEP) and unaffected controls are organized such that all researchers applying for tissue received samples from the same cohort. The SMRI was the first to include multiple diagnostic categories in the cohorts as well as the first to include a large number (N) of cases in each group. The Stanley Neuropathology Consortium (SNC) was the first cohort established and contains 60 brains (15 in each of 4 groups); it was the largest cohort of subjects with major mental illness that was available when the cohort was established in 1997. The Array Collection (AC) was a subsequent cohort with an N of 35 in each of 3 groups and was established in 2002. Pathologists from the offices of designated medical examiners in the USA were trained in standardized collection techniques. All medical and psychiatric records were obtained and reviewed by two senior psychiatrists. A psychiatrist also contacted one or more family members by telephone to clarify and verify before making the final DSM-IV diagnosis. For the normal controls, a psychiatrist conducted a structured telephone interview with first-degree family members to obtain all pertinent psychiatric and medical history as described in Torrey et al., 2000 [1]. A pathologist performed a standard neuropathological examination for every case. While cases were relatively young (average age 45 years), all brains were screened for the presence of cardiovascular disease, hemorrhage, trauma, tumors, or other pathology and confirmed by the examination of appropriate sections from the suspect area. Cases were also screened for Alzheimer’s disease, Parkinson’s disease, ethanol-induced changes, and anoxic/hypoxic-related alterations and also for RNA integrity. Only brains that were free from pathology and that had intact RNA were included in the final research cohorts. Controls have no history of any neurologic or psychiatric disorder. Within each research cohort the diagnostic groups and controls were matched for age, sex, race, postmortem interval (PMI), pH, and side of brain frozen. …
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Torrey EF, Webster M, Knable M, Johnston N, Yolken RH. The stanley foundation brain collection and neuropathology consortium. Schizophr Res 2000, 44: 151–155.CrossRefPubMed Torrey EF, Webster M, Knable M, Johnston N, Yolken RH. The stanley foundation brain collection and neuropathology consortium. Schizophr Res 2000, 44: 151–155.CrossRefPubMed
3.
Zurück zum Zitat Yan X, Mai L, Lin C, He W, Yin G, Yu J, et al. CSF-based analysis for identification of potential serum biomarkers of neural tube defects. Neurosci Bull 2017, 33: 436–444.CrossRefPubMedPubMedCentral Yan X, Mai L, Lin C, He W, Yin G, Yu J, et al. CSF-based analysis for identification of potential serum biomarkers of neural tube defects. Neurosci Bull 2017, 33: 436–444.CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Kim S, Webster MJ. The stanley neuropathology consortium integrative database: a novel, web-based tool for exploring neuropathological markers in psychiatric disorders and the biological processes associated with abnormalities of those markers. Neuropsychopharmacology 2010, 35: 473–482.CrossRefPubMed Kim S, Webster MJ. The stanley neuropathology consortium integrative database: a novel, web-based tool for exploring neuropathological markers in psychiatric disorders and the biological processes associated with abnormalities of those markers. Neuropsychopharmacology 2010, 35: 473–482.CrossRefPubMed
5.
Zurück zum Zitat Huitinga I, Webster MJ. Brain Banking. Elsevier, 2018. Huitinga I, Webster MJ. Brain Banking. Elsevier, 2018.
6.
Zurück zum Zitat Kim S, Webster MJ. Integrative genome-wide association analysis of cytoarchitectural abnormalities in the prefrontal cortex of psychiatric disorders. Mol Psychiatry 2011, 16: 452–461.CrossRefPubMed Kim S, Webster MJ. Integrative genome-wide association analysis of cytoarchitectural abnormalities in the prefrontal cortex of psychiatric disorders. Mol Psychiatry 2011, 16: 452–461.CrossRefPubMed
8.
9.
Zurück zum Zitat Kim S, Cho H, Lee D, Webster MJ. Association between SNPs and gene expression in multiple regions of the human brain. Transl Psychiatry 2012, 2: e113.CrossRefPubMedPubMedCentral Kim S, Cho H, Lee D, Webster MJ. Association between SNPs and gene expression in multiple regions of the human brain. Transl Psychiatry 2012, 2: e113.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci. Nature 2014, 511: 421–427.CrossRefPubMedCentral Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci. Nature 2014, 511: 421–427.CrossRefPubMedCentral
12.
Zurück zum Zitat Cascante A, Klum S, Biswas M, Antolin-Fontes B, Barnabe-Heider F, Hermanson O. Gene-specific methylation control of H3K9 and H3K36 on neurotrophic BDNF versus astroglial GFAP genes by KDM4A/C regulates neural stem cell differentiation. J Mol Biol 2014, 426: 3467–3477.CrossRefPubMed Cascante A, Klum S, Biswas M, Antolin-Fontes B, Barnabe-Heider F, Hermanson O. Gene-specific methylation control of H3K9 and H3K36 on neurotrophic BDNF versus astroglial GFAP genes by KDM4A/C regulates neural stem cell differentiation. J Mol Biol 2014, 426: 3467–3477.CrossRefPubMed
13.
14.
Zurück zum Zitat Seeman P. Targeting the dopamine D2 receptor in schizophrenia. Expert Opin Ther Targets 2006, 10: 515–531.CrossRefPubMed Seeman P. Targeting the dopamine D2 receptor in schizophrenia. Expert Opin Ther Targets 2006, 10: 515–531.CrossRefPubMed
15.
Zurück zum Zitat Coyle JT. The glutamatergic dysfunction hypothesis for schizophrenia. Harv Rev Psychiatry 1996, 3: 241–253.CrossRefPubMed Coyle JT. The glutamatergic dysfunction hypothesis for schizophrenia. Harv Rev Psychiatry 1996, 3: 241–253.CrossRefPubMed
Metadaten
Titel
The Stanley Neuropathology Consortium Integrative Database (SNCID) for Psychiatric Disorders
verfasst von
Sanghyeon Kim
Maree J. Webster
Publikationsdatum
01.04.2019
Verlag
Springer Singapore
Erschienen in
Neuroscience Bulletin / Ausgabe 2/2019
Print ISSN: 1673-7067
Elektronische ISSN: 1995-8218
DOI
https://doi.org/10.1007/s12264-018-0314-7

Kompaktes Leitlinien-Wissen Neurologie (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Neu im Fachgebiet Neurologie

Neuartige Antikörpertherapie bremst MS über zwei Jahre hinweg

Eine Therapie mit dem C40-Ligand-Blocker Frexalimab kann MS-Schübe und neue MRT-Läsionen über zwei Jahre hinweg verhindern. Dafür spricht die Auswertung einer offen fortgeführten Phase-2-Studie.

Positive Phase IIb-Studie zu mRNA-gestützter CAR-T bei Myasthenia gravis

Eine auf das B-Zell-Reifungsantigen gerichtete mRNA-basierte CAR-T-Zell-Therapie wurde jetzt in einer ersten Phase IIb-Studie zur Behandlung der generalisierten Myasthenia gravis mit Placebo verglichen.

Therapiestopp bei älteren MS-Kranken kann sich lohnen

Eine Analyse aus Kanada bestätigt: Setzen ältere MS-Kranke die Behandlung mit Basistherapeutika ab, müssen sie kaum mit neuen Schüben und MRT-Auffälligkeiten rechnen.

Schadet Schichtarbeit dem Gehirn?

Eine große Registerstudie bestätigt, dass Schichtarbeit mit einem erhöhten Risiko für psychische und neurologische Erkrankungen einhergeht, sowie mit einer Volumenabnahme in Gehirnarealen, die für Depression, Angst und kognitive Funktionen relevant sind.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.